Most patients with Hodgkin Lymphoma (HL) achieve long-term remission after adequate first-line treatment.
Nonetheless, follow-up care is important for several reasons.
Firstly, the risk for HL recurrence appears to be increased for 20 years after initial diagnosis (Bröckelmann et al., J Clin Oncol, 2017).
Secondly, a relevant proportion of patients develop treatment-related late effects including second malignancies. The recently published 10-year follow-up analysis of the randomized GHSG HD15 study for patients with advanced HL revealed a second malignancy rate of 7% (Engert et al., Hemasphere, 2017).
Coronary heart disease and fatigue represent other late sequelae causing relevant morbidity and mortality (van Nimwegen et al., J Clin Oncol, 2016; Kreissl et al., Lancet Oncol, 2016).
Given the need of post-treatment surveillance in HL patients, follow-up and survivorship aspects will represent a major focus of ISHL11.
Please pay particular attention to our submission guidelines as these have changed. For the first time, you may apply for a poster pitch.
It covers the most recent advances in basic research, diagnostics, treatment and follow-up of Hodgkin lymphoma…
We are pleased to announce that the online registration for ISHL11 is now open! Early bird registration ends on May 31, 2018.
Treatment stratification by PET/CT has improved outcome and reduced treatment toxicity in Hodgkin Lymphoma. Recently, results of the GHSG HD18 trial were presented at EHA 2017. In this study…
Latest Results of Large Scale Randomized Phase Ⅲ Trials in Advanced Stage HL
One central question in Hodgkin Lymphoma is the best treatment for advanced stage patients. Initial data of the company-sponsored international ECHELON-1 trial were expected with substantial interest and will be presented at ASH 2017 in detail…